## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($59.67)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Pomerantz LLP Moves to File Class Action Against DexCom, Inc. – DXCM**
- Source: KLAS 8 News Now | 20251202T070000 | Neutral | Relevance: 99%
- Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) and certain officers, alleging federal securities law violations. The lawsuit claims DexCom made materially false and misleading statements regarding its G6 and G7 continuous glucose monitoring systems, particularly concerning unauthorized design changes that rendered the devices less reliable and posed health risks. The action seeks damages for investors who purchased DexCom securities between July 26, 2024, and September 17, 2025.

**2. DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: KTLA | 20251202T075500 | Neutral | Relevance: 99%
- Lieff Cabraser Heimann & Bernstein, LLP is encouraging investors in DexCom, Inc. (NASDAQ:DXCM) to join a securities class action lawsuit, with a lead plaintiff deadline of December 26, 2025. The lawsuit alleges that DexCom made false and misleading statements regarding material design changes to its G6 and G7 continuous glucose monitoring systems without FDA approval, leading to inaccurate readings and potential patient harm. These issues reportedly caused significant drops in DexCom's stock price following negative financial results, an FDA Warning Letter, and analyst downgrades, resulting in a $12.4 billion loss in market capitalization.

**3. DXCM Shareholders Have Opportunity to Lead DexCom, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!**
- Source: WTRF | 20251130T070000 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) and certain officers for alleged violations of federal securities laws. The lawsuit claims DexCom made false and misleading statements regarding unauthorized material design changes to its G6 and G7 devices, which allegedly rendered them less reliable and posed health risks to users. Investors who purchased DexCom securities between January 8, 2024, and September 17, 2025, are encouraged to join the lawsuit, with a lead plaintiff deadline of December 26, 2025.

**4. DXCM DEADLINE: DexCom, Inc. Investors Encouraged to Contact Kirby McInerney LLP Before Looming Deadline in Lawsuit**
- Source: www.yourerie.com | 20251202T180000 | Neutral | Relevance: 99%
- Kirby McInerney LLP is urging investors of DexCom, Inc. (NASDAQ: DXCM) to contact them by the December 26, 2025 deadline to act as lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that DexCom made misleading statements regarding unauthorized FDA design changes to its G6 and G7 glucose monitoring devices, leading to reliability issues and significant stock declines following regulatory warnings, analyst downgrades, and a critical report from Hunterbrook Media. Investors who suffered losses between January 8, 2024, and September 17, 2025, are affected.

**5. Pomerantz LLP Moves to File Class Action Against DexCom, Inc. – DXCM**
- Source: WDHN | 20251202T070000 | Neutral | Relevance: 99%
- Pomerantz LLP has initiated a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) and its officers, alleging that the company made false and misleading statements about its G6 and G7 continuous glucose monitoring systems. The lawsuit claims that DexCom implemented unauthorized design changes, rendering the devices less reliable and posing health risks, which led to significant stock price drops following an FDA warning letter, an analyst downgrade, and a critical report from Hunterbrook. Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, have until December 26, 2025, to seek appointment as lead plaintiff.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 14.5% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.86 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (1 raises, avg +19%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.5B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.86 |
| Forward P/E | 25.9 |
| Current P/E | 31.2 |
| YoY Growth | 20.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 2.1% (minimal 5-day change). Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. Below SMA200 (0.85x), long-term trend not supportive. MACD histogram positive (0.96), confirming momentum. RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.06% (CS: 84) | Neutral |
| RSI_14 | 56.4 | Neutral |
| MACD Histogram | 0.96 | Bullish |
| vs SMA20 | 1.075x | Above |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 0.855x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $64.45
- **Stop Loss:** $59.67 (7.4% risk)
- **Target:** $69.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 209
- **Position Value:** $13,470.05
- **Portfolio %:** 13.47%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*